Adage Capital Partners GP L.L.C. Has $10.64 Million Holdings in TScan Therapeutics, Inc. (NASDAQ:TCRX)

Adage Capital Partners GP L.L.C. reduced its stake in shares of TScan Therapeutics, Inc. (NASDAQ:TCRX - Free Report) by 20.5% during the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 3,500,000 shares of the company's stock after selling 900,000 shares during the period. Adage Capital Partners GP L.L.C. owned approximately 6.56% of TScan Therapeutics worth $10,640,000 as of its most recent filing with the SEC.

A number of other institutional investors have also recently bought and sold shares of the stock. State Street Corp lifted its holdings in shares of TScan Therapeutics by 24.4% in the third quarter. State Street Corp now owns 756,499 shares of the company's stock valued at $3,767,000 after purchasing an additional 148,414 shares in the last quarter. Barclays PLC lifted its stake in TScan Therapeutics by 341.1% in the 3rd quarter. Barclays PLC now owns 58,067 shares of the company's stock valued at $289,000 after acquiring an additional 44,903 shares in the last quarter. Geode Capital Management LLC boosted its position in TScan Therapeutics by 8.1% during the 3rd quarter. Geode Capital Management LLC now owns 973,466 shares of the company's stock worth $4,849,000 after acquiring an additional 72,967 shares during the last quarter. JPMorgan Chase & Co. grew its stake in shares of TScan Therapeutics by 94.4% during the 3rd quarter. JPMorgan Chase & Co. now owns 31,805 shares of the company's stock worth $158,000 after acquiring an additional 15,441 shares in the last quarter. Finally, SG Americas Securities LLC raised its holdings in shares of TScan Therapeutics by 31.2% in the fourth quarter. SG Americas Securities LLC now owns 20,415 shares of the company's stock valued at $62,000 after purchasing an additional 4,852 shares during the last quarter. Institutional investors own 82.83% of the company's stock.

Analysts Set New Price Targets

A number of research firms recently weighed in on TCRX. Morgan Stanley reaffirmed an "overweight" rating and issued a $10.00 target price on shares of TScan Therapeutics in a research report on Friday, March 14th. Needham & Company LLC reaffirmed a "buy" rating and issued a $9.00 target price on shares of TScan Therapeutics in a research report on Tuesday, April 8th. Wedbush reiterated an "outperform" rating and set a $7.00 target price on shares of TScan Therapeutics in a report on Wednesday, March 5th. HC Wainwright restated a "buy" rating and issued a $15.00 price target on shares of TScan Therapeutics in a research note on Thursday, March 6th. Finally, Barclays dropped their price objective on TScan Therapeutics from $14.00 to $3.00 and set an "overweight" rating on the stock in a research note on Friday, March 7th. Six investment analysts have rated the stock with a buy rating, According to MarketBeat, TScan Therapeutics has a consensus rating of "Buy" and an average price target of $9.33.

TScan Therapeutics Stock Performance

TScan Therapeutics stock traded up $0.05 during midday trading on Friday, reaching $1.60. 348,423 shares of the company's stock were exchanged, compared to its average volume of 360,140. The stock's 50-day simple moving average is $1.55 and its 200 day simple moving average is $2.84. The firm has a market cap of $90.55 million, a price-to-earnings ratio of -1.51 and a beta of 1.09. The company has a debt-to-equity ratio of 0.13, a quick ratio of 9.56 and a current ratio of 9.56. TScan Therapeutics, Inc. has a 52 week low of $1.02 and a 52 week high of $9.69.

TScan Therapeutics (NASDAQ:TCRX - Get Free Report) last issued its earnings results on Wednesday, March 5th. The company reported ($0.29) EPS for the quarter, missing the consensus estimate of ($0.27) by ($0.02). The business had revenue of $0.67 million for the quarter, compared to the consensus estimate of $1.43 million. TScan Therapeutics had a negative return on equity of 58.72% and a negative net margin of 1,188.88%. On average, analysts expect that TScan Therapeutics, Inc. will post -1.12 earnings per share for the current fiscal year.

About TScan Therapeutics

TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.